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reSULTS aND recommeNDaTIoNS
 ❚ Health is a public good, just like education or security and its “return on investment” 
seems high. A key component for delivery of this public good is a combination of 
absolutely vital but limited public funding and private-sector financing.  
 ❚ In the post-2015 agenda, it is vital to demonstrate the actionable scope of Univer-
sal Health Coverage (UHC) to facilitate its implementation. For this, further research 
needs to be mobilised in order to develop indicators to measure the effectiveness of 
health systems and services, as well as prevention. Increasing our empirical knowl-
edge of the performance of health systems is a prerequisite for improving them.  
 ❚ It would also be useful to undertake a full review of innovations in health financing 
(air ticket levy scheme, International Finance Facility for Immunisation, Advanced 
Market Commitment, debt conversions, Product (RED) initiative) and open this up 
to discussion in view of the new SDGs and the need for deeper involvement of the 
private sector.
 ❚ France could further consolidate and develop the comparative advantages of its of-
ficial development assistance for health (DAH). French DAH borders on 750 million 
euros but is still relatively invisible and unknown to the general public. A large swathe 
of French aid is channelled through vertical funds, in whose stewardship France has 
engaged with limited human resources.
The year 2015 and the formulation of the sustainable develop-ment goals (SDGs) will be arriving at a time when changes in the ecosystem of official development assistance for health (DAH) are in full swing. The consensus for an ambi-tious “Health SDG” for 2030, targeting both diseases and 
health systems, precludes a status quo in the amounts of funding flows 
and makes it unlikely that the current structure of the DAH ecosystem 
will be maintained. The major unknown is how the existing model—
designed around and for the Millennium Development Goals (MDGs) 
and which has proved highly effective for some of them—will transition 
to a model that will ensure the universal health SDGs are achieved, but 
which is yet to be invented. In what direction does France wish to propel 
this reform and how does it envision the transition from one model to 
the other, in harmony with the models that the other development aid 
players foresee? The purpose of this Policy Brief is to gather some initial 
answers to these two questions.
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1. aN ImPreSSIve recorD For DaH
Unquestionable progress in global health. The 
progress measured since the World Bank released 
its report Investing in Health (World Bank, 1993) 
speaks for itself. In most countries, populations 
have seen their life expectancy increase – even 
doubled in countries like China, Mexico, Ethiopia 
and India; at global level, the number of deaths 
of children under five years of age has dropped 
from some 12 million to fewer than 7 million, while 
the maternal mortality rate has been halved (The 
Lancet, 2013). Advances in healthcare have on 
average been more spectacular for women than for 
men, with the notable exception of China and India 
(ibid.). 
The reasons for this progress hinge on a combi-
nation of factors: technical progress (equipment, 
drugs, vaccines), the inclusion of public health is-
sues on the agendas of the least developed coun-
tries (LDCs) and middle-income countries (MICs), 
a spectacular rise of income in countries that have 
graduated to MIC status and the mobilisation of 
hefty amounts of official development assistance. 
However, the funds dedicated to health R&D rose 
fivefold between 1990 and 2010, 60% of which 
were disbursed by the private sector and mainly 
funnelled to non-communicable diseases (NCDs). 
Fewer than 2% are allocated to the infectious dis-
eases of prime concern to LDCs and MICs.  
Innovative intervention mechanisms based on 
measurement of results. Institutional innovations 
were first rolled out in R&D with the 1996 launch 
of the first public-private product development 
partnership (PPPDP) funded by the Rockefeller 
Foundation, followed by an injection of funds from 
the Bill et Melinda Gates Foundation (BMGF) and 
public-sector donors. Virtually absent before 2000, 
public-private partnerships (PPPs) now account 
for almost 20% of contributions in 2013. Most of 
this new financing is through vertical programmes 
aimed at combatting HIV/AIDS, tuberculosis and 
malaria via the introduction of new vaccines, which 
are allocated in priority to East and West sub-Saha-
ran African geographies (The Lancet, 2013). Meas-
uring the performance of cooperation initiatives 
in the area of health using results indicators was a 
determining factor for the stepping-up of financial 
commitments from both public donors and private 
actors around the MDGs 4, 5 and 6.
Large-scale political and financial mobilisation, in-
cluding France. Official development assistance for 
health rose fivefold between 1990 and 2013 (IHME, 
2013) to reach just over 31 billion dollars. Bilateral 
aid is still the first financing channel, varying be-
tween 50% of contributions in 1990 and about 30% 
during the slack years 2000–2001. France holds a 
significant place in this ecosystem due to its politi-
cal leadership, notably in the creation of the Global 
Fund and International Finance Facility for Immu-
nisation (IFFIm/GAVI). France contributes some 
750 million euros comprising 80% in multilateral 
aid and 20% in bilateral aid. 
2. PoST-2015 cHaLLeNgeS
“Finish the MDG job”. As the WHO underlines, 
“The current trends form a good basis for intensi-
fied collective action and expansion of successful 
approaches to overcome the challenges posed 
by multiple crises and large inequalities” (WHO, 
2013). However, progress is uneven both within 
and between countries. The countries of France’s 
priority intervention zone1 record the least satisfac-
tory results, whereas their needs are constantly on 
the rise, driven by high demographic growth. 
A thematic and geographic rebalancing of DAH.  In 
2011, sub-Saharan Africa received 28.6  of total DAH 
with nearly 9 billion dollars. By sector or theme, the 
HIV/AIDS item is the leading recipient, with near-
ly 8 billion dollars; maternal, newborn and child 
health is an increasing item, reaching 6 billion dol-
lars, whereas the 377 million dollars dedicated to 
non-communicable diseases is derisory compared 
to the total. Many countries that bear the heavi-
est disease burden do not receive a proportional 
amount of attention and DAH financing (IHME, 
2013). Among the top-twenty country ranking for 
disability-adjusted life years (DALY), only thirteen 
are present in the top-twenty DAH recipients. 
Broadening the health agenda. The rise in “man-
made” or environment-induced diseases (diabetes, 
hypertension, heart disease and cancer) is symp-
tomatic of the epidemiological transition in many 
developing countries. The health agenda is being 
widened to include non-communicable diseases, 
sanitary issues and prevention. 
Health systems are core to the post-2015 agenda. 
Broadening the health agenda brings the DAH 
model into question. The need to support health 
systems is becoming increasingly evident, with 
specific focus on all types of primary healthcare 
and hospitals. However, the new challenge of 
strengthening health systems is less easily adapt-
able to performance measurement via results 
indicators. 
Increasing financing needs. The success of DAH 
places the growing ambitions for health issues on 
1. Benin, Burkina Faso, Burundi, Djibouti, The Comoros, 
Ghana, Guinea, Madagascar, Mali, Mauritania, Niger, 
Central African Republic, Democratic Republic of the 
Congo, Chad, Togo, Senegal.
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a sound footing, but meeting these ambitions will 
be tough if budgets are not increased. On the one 
hand, the uncertainty surrounding the marginal 
abatement cost for some diseases  does not allow 
us to conclude, for example, that “finishing” the 
work begun on the MDGs 4, 5, and 6 will be possi-
ble at a cost necessarily lower than the expenditure 
incurred thus far. Moreover, a broadened agenda 
and the focus on health systems challenge not only 
the PPP model that has been driving recent pro-
gress but also the needs and sources of financing.  
New donor fatigue. Innovative vertical funds 
furnished a response to emergency situations but 
they are not intended to be permanent. At the 
same time, putting a series of objectives (sustain-
able development goals – SDGs) involving subjects 
as diverse as education, hunger, agriculture, biodi-
versity or energy on the sustainable development 
agenda raises the concern that ODA operators’ 
support for health questions could gradually wane, 
following ten years of increasing commitments. 
Strengthening health systems and mobilising re-
sources. As they operate in emergency situations, 
vertical funds have had to circumvent the diffi-
culties linked to the shortcomings of local health 
systems, even if this has sometimes meant further 
destabilising them. What has now become urgent 
is to build robust and lasting health systems. This 
means identifying local needs in the absence of 
any precise definition of primary health needs, 
better access to services and higher service qual-
ity, improved infrastructures, the strengthening 
of legal frameworks, technical and administra-
tive capacities, innovative financing models, and 
appropriate methods of collecting, analysing and 
disseminating information at local level. 
Dialogue and cooperation between DAH actors. 
The effectiveness of the overall health aid ecosys-
tem can be improved. Studies highlight the lack 
of coordination between actors, the risk of dupli-
cating and fragmenting activities, the confusion 
about what the actors and communities concerned 
expect of the different donors’ role, and a pos-
sible negative effect on national health policies 
(Biesma, Brugha, Harmer, Walsh, Spicer & Walt, 
2009; Kerouedan, 2010; McCoy, Bruen, Hill & Ker-
ouedan, 2012; The Lancet, 2013; Moon & Omole, 
2013). The focus on strengthening health systems 
underlines the importance of a more productive 
dialogue on the definition of health needs, more 
effective donor cooperation and a real coherence 
between national policies and donors. The capac-
ity to engage in dialogue is open to question in the 
case of standard-producing institutions like the 
WHO, whose regular budgets have been shrinking 
in real terms since 1994 (The Lancet, 2013; IHME, 
2012; Legge, 2012), as well as in some recipient 
countries where changes in the budgets dedicated 
to health are still not correlated with their popula-
tions’ growing needs. 
3. THe FreNcH reSPoNSeS
Today, France wishes to capitalise on the lessons 
learnt over the past decade. It supports the imple-
mentation of the MDGs, with priority set on the fight 
against HIV/AIDS, tuberculosis, malaria, maternal 
and newborn health and the fight against neglected 
tropical diseases. In parallel, it is promoting a struc-
tural approach to health (health systems) that 
integrates the fight against pandemics and social 
protection floors. The emphasis is on an overall 
approach to health encompassing both social and 
environmental determinants and involving the right 
to health, access to drugs and healthcare though a 
universal health coverage (UHC). It is advocating 
this approach within the United Nations system 
to ensure that this objective becomes a focal point 
of the SDGs. France considers that UHC makes 
it possible to tackle unequal access to healthcare 
services and the financial risks linked to people’s 
spending on health (MAEE, 2013b). However, UHC 
is facing hefty obstacles to its implementation and 
evaluation. Today, for want of a concerted interna-
tional initiative, health systems are being strength-
ened – which is a sine qua non for setting up UHC 
– exclusively on a bilateral basis through the French 
Agency for Development (AFD).
The focus on UHC raises several questions:
 m What can be done to strengthen the AFD’s means 
of action to consolidate health systems, in line 
with France’s continuing commitment to the ver-
tical funds it has supported and which have pro-
ved their effectiveness? 
 m What choice of objectives and performance indi-
cators can be suggested in the near term? 
 m What coordination can be set up between French 
action and that of the other donors? 
 m What budget commitments can be made to sup-
port public policies (heath and social protection), 
human resources development, health infras-
tructures and cross-sector challenges (education, 
water, food security, etc.)?
 m To what extent are the French guidelines for 
health aid compatible with the priorities of reci-
pient countries? 
France proposes the use of innovative financ-
ing instruments, such as a financial transaction 
tax, to ensure a steady flow of funds not subject 
to the impact of budget cycles. And above all, the 
concomitant mobilisation of partner countries’ na-
tional budgets, since UHC is the responsibility of 
each State (Araud, 2014; MAEE, 2013b). In terms of 
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instruments, it stresses the importance of technical 
assistance, and yet this was the victim of choice for 
the French aid reform (Voituriez, Giordano, Bous-
sichas, 2014).
4. oUr recommeNDaTIoNS
Health is a public good, just like education or 
security. Its “return on investment” seems high 
(The Lancet, 2013). A key component for delivery 
of this public good, on a level with the challenges 
outlined in this brief, lies in a combination of abso-
lutely vital, but limited, public funds and private-
sector financing. Yet, whatever the amounts made 
available through these different channels, official 
development assistance (ODA) remains an indis-
pensible tool as it has a triple role: catalysing funds, 
funding specific schemes that would never attract 
finance from the marketplace and providing health-
related knowledge gathered over many decades. 
In this setting, France has the opportunity to fur-
ther consolidate and develop the comparative ad-
vantages of its development assistance for health 
(DAH). It could reap the benefits by: 
 m communicating more incisively on the its ODA 
funding commitments as well as on their out-
comes. French DAH borders on 750 million euros 
but is still relatively invisible and unknown to the 
general public;
 m investing more deeply in the governance of ver-
tical funds: a large portion of French aid is fun-
nelled through vertical funds, but French parti-
cipation in their stewardship mobilises limited 
human resources, even though there is real room 
for influence both globally and in local-level 
implementation;  
 m making more extensive and more effective use 
of its high quality health expertise. For instance, 
no French national or French-speaker has a seat 
on the WHO’s SAGE Committee, even though 
there is no lack of competencies. Likewise, the 
“strike force” of the health agencies is not fully 
exploited. What’s more, France has an original 
health-care model in place that could well ins-
pire other countries, even though this is in need 
of some reform.  
For the post-2015 agenda, it is vital to demonstrate 
the actionable scope of Universal Health Coverage 
(UHC) agenda so that it can be implemented swiftly 
and efficiently after 2015. To this end, it is worthwhile 
mobilising further research to develop indicators on 
the effectiveness of health systems and services, as 
well as on prevention. 
It would also be useful to undertake a full re-
view of innovations in health financing (air ticket 
levy scheme, International Finance Facility for 
Immunisation, Advanced Market Commitment, 
debt conversion, Product (RED) initiative) – including 
but not limited to financial engineering – and open 
this up to discussion in view of the new SDGs and the 
need for deeper involvement of the private sector.  
reFereNceS
Afd. (2012). Cadre d’intervention sectoriel sante et protection 
sociale 2012–2014.
Araud, G. (2014). Intervention de M. Gérard Araud, 
représentant permanent de la France auprès des Nations 
unies. Couverture Sanitaire Universelle : Comment la mettre 
en uvre et lévaluer. http://www.franceonu.org/la-france-
a-l-onu/espace-presse/interventions-en-seance-publique/
autres-instances/article/14-avril-2014-couverture-sanitaire
Biesma R, Brugha R, Harmer A, Walsh A, Spicer N, Walt 
G. The effects of global health initiatives on country health 
systems: A review of the evidence from HIV/AIDS control. 
Health Policy Plan 2009; 24: 239–52.
Institute for Health Metrics and Evaluation (IHME). 
Financing global health 2012: the end of the golden age? 
http://www.healthmetricsandevaluation.org/ publications/
policy-report/fi nancing-global-health-2012-end-golden-age 
(accessed Feb. 12, 2013). 
Kerouedan, D. (2010). Enjeux politiques de lévaluation à cinq 
ans du Fonds Mondial de lutte contre le sida, la tuberculose et 
le paludisme. Médecine Tropicale 2010: 70; 19–27.
Lancet (2013). Global Health 2035: a world converging 
within a generation. Vol. 382, December 7, 2013.
Legge D. (2012). Future of WHO hangs in the balance. BMJ 
2012; 345: e6877.
MAEE. (2011). La stratégie de la France pour la coopération 
internationale dans le domaine de la santé. Paris.
MAEE. (2013a). Compte rendu de la table ronde santé 
(2B) du 8 janvier 2013. Assises du développement et de la 
solidarité internationale. Paris.
MAEE. (2013b). La France et la couverture sanitaire 
universelle. Fiche repère. Paris: Ministère des Affaires 
Etrangères.
McCoy, D., Bruen, C., Hill, P., Kerouedan, D. (2012). The 
Global Fund: What Next for Aid Effectiveness and Health 
Systems Strengthening? AIDSPAN, 20 April 2012. 20p. www.
aidspan.org. 
Moon S, Omole O (2013). Development Assistance for 
Health: Critiques and Proposals for Change. Draft Chatham 
House background paper http://www.chathamhouse.org/
publications/papers/view/190951 (accessed Oct. 17, 2013).
Voituriez T., Giordano T., Boussichas M. (2014). “Post-
2015 development challenges: implications for official 
development assistance”, IDDRI Policy Brief no. 07/14 
March.
WHO (2013). Monitoring the achievement of health-related 
Millennium Development Goals. Report by the Secretariat. 
A66/13. 14 May 2013. Geneva 
World Bank (1993). Investing in Health World Development 
Report, World Bank, Washington, DC.
